Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | MGLL | Q99685 | 4/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430211 | 0.90 | MGLL (0.54) | YAP1MGLLPRMT5OPRD1OPRK1 | |
| SCHEMBL3346536 | 0.87 | MGLL (0.48) | MGLL | |
| SCHEMBL3346543 | 0.87 | MGLL (0.48) | MGLL | |
| SCHEMBL18418311 | 0.87 | MGLL (0.52) | MGLLOPRD1OPRK1GPR119TACR1 | |
| SCHEMBL22880757 | 0.87 | MGLL (0.52) | MGLLOPRD1OPRK1GPR119TACR1 | |
| SCHEMBL2425892 | 0.84 | MGLL (0.53) | MGLLGPR119TACR1 | |
| SCHEMBL2427632 | 0.84 | MGLL (0.53) | MGLLGPR119TACR1 | |
| SCHEMBL2424910 | 0.84 | MGLL (0.53) | MGLLGPR119TACR1 | |
| SCHEMBL22193619 | 0.82 | PRMT5 (0.61) | YAP1PRMT5GPR119STS | |
| SCHEMBL2430613 | 0.81 | MGLL (0.47) | MGLLGPR119TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | YAP1 4289/4885MGLL 246/4885PRMT5 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.